BioBehavioral Diagnosis Co (BioBDx), a developer of attention deficiency/hyperactivity disorder (ADHD) testing devices, raised $5. 1 million in a round of venture capital, according to a new filing by the company to the Securities and Exchange Commission. Five separate investors participated in the bid.
The firm’s Quotient ADHD System accurately measures motion and analyzes shifts in attention to give a clear picture of the core symptom areas of ADHD (also known as ADD) even in the presence of conditions other than ADHD. The Quotient ADHD Test Report should only be interpreted by qualified professionals in conjunction with other clinical information.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/BioBehavioral%20Diagnostic/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
